FWIW that CEO setup where we are now as it was under his leadership that the initial target of Alzheimer’s was established. In fact, he stepped up further after leaving with his hard earned cash by exercising his options. He has continued to invest so clearly is a believer in the opportunity but DYOR. Perhaps Gourlay was simply executing something that had been already set in motion before his appointment as CEO!
Ann: ACW XanaCIDD depression trial results expected early August, page-86
-
- There are more pages in this discussion • 22 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
